Carbamazepine and lithium carbonate synergism in mania.

  title={Carbamazepine and lithium carbonate synergism in mania.},
  author={Robert M. Post and Thomas W Uhde},
  journal={Archives of general psychiatry},
  volume={41 2},
  • R. PostT. Uhde
  • Published 1 February 1984
  • Medicine, Psychology
  • Archives of general psychiatry
To the Editor.— Moss and James 1 presented an interesting case of an acute but unsustained antimanic response to the combination of carbamazepine and lithium carbonate. Several points raised in their letter deserve comment and further discussion. There are many potential reasons for the lack of a continued response to carbamazepine in combination with lithium carbonate in their case. One is dosage. The 800-mg/day dosage they employed was slightly below the average dosage in our series, with… 

Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment‐resistant mania

Six of 7 manic patients who had previously been largely refractory to lithium alone, and who still showed substantial mania after several weeks of double‐blind treatment with carbamazepine, improved following the blind addition of lithium.

Non-lithium pharmacological treatment of manic depression: a review

  • B. O'Shea
  • Psychology, Medicine
    Irish Journal of Psychological Medicine
  • 1993
In view of the 20-25% of patients who do not respond to lithium, and the increased likelihood that lithium-responders may fail to respond again once the drug has been stopped for a period, further research is needed to find better and safer prophylactics against depression in bipolar disorders.

Influence of lithium on the anticonvulsant activity of carbamazepine.

Lithium potentiated the anticonvulsant effect of CBZ against PTZ-induced convulsions and lithum did not alter the anticonsvulsive effect ofCBZ.

Therapeutic concentrations of lithium and carbamazepine inhibit cGMP accumulation in human lymphocytes

Therapeutic concentrations of both drugs inhibit sodium nitroprusside-induced accumulation of cGMP in human lymphocytes to about the same extent, and it is speculated that the individual sensitivity of the cG MP generating system of human lymphocyte to both drugs might be used to predict therapeutic response or nonresponse of the individual patient.

Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness.

Assessment of the dopamine metabolite homovanillic acid in the cerebrospinal fluid of affectively ill patients provides further evidence that carbamazepine does not have a biochemical profile typical of neuroleptics.

The Phenomenology of Psychosis Associated with Complex Partial Seizure Disorder

The author reviews the available literature relevant to the clinical phenomenology and treatment of this topic and illustrates the clinical profiles of 10 treatment-refractory patients admitted to a state hospital with previously undiagnosed psychoses secondary to CPSD.

Adjunctive treatment of acute mania: a clinical overview

An overview of the available high quality evidence‐base of studies of adjunctive pharmacologic treatment for acute mania is provided.

Neuropsychiatry and Behavioral Pharmacology

The book explores the neuropsychiatric consequences of congenital and acquired brain lesions and their appropriate pharmacologic treatment. The clinical problems addressed are the severe behavioural



Carbamazepine and lithium carbonate synergism in mania.

A favorable but brief response to that combination of lithium carbonate and carbamazepine is reported in a patient who had not responded adequately to either drug alone.

Effect of carbamazepine in polyuria associated with lithium therapy.

  • K. Ghose
  • Medicine, Psychology
    Pharmakopsychiatrie, Neuro-Psychopharmakologie
  • 1978
It appears that lithium exacerbates carbamazepine induced CNS side-effects or vice versa, the mechanism of which is not very clear, and simultaneous administration of these two drugs should preferably be avoided.

Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications

  • R. Post
  • Psychology, Medicine
    Psychological Medicine
  • 1982
Improvement was particularly notable in 2 patients with severe and fulminant rapidly cycling manic-depressive illness who had required essentially continuous state hospitalization for several decades prior to admission to NIMH, suggesting the potential usefulness of carbamazepine for treatment-resistant and rapidly cycling patients.

Clinical Pharmacokinetics of Carbamazepine

A single daily dose of carbamazepine is insufficient; 2 doses per day are appropriate in most cases, but some patients may benefit from more frequent dosing to avoid side-effects.

Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response.

The possibility that the -10,11-epoxide metabolite of carbamazepine may be related to the degree of clinical efficacy in affectively ill patients and may thus possess active psychotropic properties in man in addition to its reported anticonvulsant effects in animals is suggested.

Biochemical effects of carbamazepine: Relationship to its mechanisms of action in affective illness

Lithium and carbamazepine interaction: possible neurotoxicity.

A 22-year-old woman with bipolar affective disorder who developed severe neurotoxic symptoms when treated with a combined regimen of lithium carbonate and carbamazepine in therapeutic doses implicated a synergistic interaction between the two medications.